Pharmaceutical Technology

AUGUST 18, 2022

A custom-made, one-dose gene therapy, Zynteglo is indicated for such patients who need red blood cells (RBCs) transfusions on a regular basis. The latest approval is based on findings from the Phase III clinical trials, HGB-207 (Northstar-2) and HGB-212 (Northstar-3), and the long-term follow-up LTF-303 study. 0 genotypes.

Gene Therapy 246

Gene Therapy Gene Genotype Genetics 246

pharmaphorum

AUGUST 31, 2022

After a recent approval, there are now three gene therapies available on the US market. In recent years, gene therapy has transitioned from a promising idea to a reality for patients, with many of the severe safety issues that emerged in early iterations of the technology being overcome. from 2021 to 2029.

Gene Therapy 98

Gene Therapy Gene Gene Editing DNA 98

pharmaphorum

JUNE 28, 2022

Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials. For sponsorship enquiries contact Luke Teachen on +44 (0) 20 7827 6002 or email: lteachen@smi-online.co.uk. By attending the conference attendees will have the opportunity to.

RNA 52

RNA Engineer Development Clinical Trials 52

The Pharma Data

JANUARY 10, 2021

However, the global COVID-19 pandemic may still adversely impact Hansa Biopharma’s operational business and trial activities. Randomized Controlled Trial in the US Hansa is in ongoing discussions with the U.S. Imlifidase as pre-treatment ahead of gene therapy in DMD and LGMD.

Gene Therapy 52

Gene Therapy Gene Antibody Trials 52

The Pharma Data

MARCH 22, 2021

VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021. Novartis is committed to reimagining prostate cancer through targeted radioligand therapy with 177 Lu-PSMA-617. The safety profile was consistent with data reported in previous clinical studies 1.

Hormones 52

Hormones Gene Therapy Trials Medicine 52

The Pharma Data

JULY 12, 2021

. “In head-to-head comparisons, we demonstrated the superiority of this approach over existing methodologies to accurately predict ‘winners’ and ‘losers’ in clinical trials,” said Ghosh. “The ‘phase 0’ trial concept was developed because most drugs fail somewhere between phases I and III.

Drugs 52

Drugs Gene Expression Big Data Gene 52

The Pharma Data

JANUARY 9, 2021

(NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Pfizer

SEPTEMBER 28, 2022

This study is consistent with regulatory guidance and follows the design of the previous Phase 1/2/3 trial to evaluate further options for protection in this age group. . 5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Pfizer

OCTOBER 19, 2022

Today’s recommendation is based on data from a Phase 2/3 randomized, controlled trial that included 4,526 children aged 6 months to less than 5 years. In the trial, children received a third 3-µg dose of the original Pfizer-BioNTech COVID-19 Vaccine at least two months after the second dose at a time when Omicron BA.2

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

The Pharma Data

SEPTEMBER 15, 2020

Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. A Phase 3 trial is ongoing. Protease Inhibitor Program. Rare Disease.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

AUGUST 2, 2023

Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. But all three drugs have new competitors. billion ($1.17

Sales 98

Sales Manufacturing FDA Approval Life Science 98